posaconazole

posaconazole
Product Description

Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity.The antifungal drug posaconazole, have potent trypanocidal activity.  Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was frequently more active than other azoles and amphotericin B.

Read more Show less

Medsyn (Chengdu) Biotechnology Co., Ltd

  • CN
  • 2023
    On CPHI since
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    171228-49-2
  • Selling Points
    Immune Health; Product Features
  • Measured In
    gram; kilogram
More specifications Fewer specifications

Medsyn (Chengdu) Biotechnology Co., Ltd

  • CN
  • 2023
    On CPHI since
View company profile

More Products from Medsyn (Chengdu) Biotechnology Co., Ltd (4)

  • Bavdegalutamide

    Product Bavdegalutamide

     Given these mechanisms of resistance, our goal is to eliminate the AR protein using the PROteolysis TArgeting Chimera (PROTAC) technology. Here we report an orally bioavailable small molecule ARV-110 that leads to ubiquitination and degradation of AR. ARV-110 completely degrades AR in all cell lines ...
  • Milvexian

    Product Milvexian

    Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.In this parallel-group, p...
  • Orforglipron

    Product Orforglipron

    Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity.In this phase 2, ...
  • Pirtobrutinib

    Product Pirtobrutinib

    Pirtobrutinib, a highly selective kinase inhibitor, utilizes a novel binding mechanism and is the first and only FDA approved non-covalent (reversible) BTK inhibitor. Jaypirca can reestablish BTK inhibition in MCL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanub...